Johnson & Johnson will pay $442.7 million for an 18% stake in Crucell and collaborate with the Dutch biotech firm to develop and market a monoclonal antibody for influenza. The deal provides "access to antibody and vaccine know-how and technology, and expands our ability to offer preventive health care solutions for unmet medical needs," a J&J official said.

Related Summaries